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Abstract
Background: Cathepsins K, L, and S are cysteine proteases upregulated in cancer and proteolyze extracellular
matrix to facilitate metastasis, but difficulty distinguishing specific cathepsin activity in complex tissue extracts
confounds scientific studies and employing them for use in clinical diagnoses. Here, we have developed multiplex
cathepsin zymography to profile cathepsins K, L, and S activity in 10 μg human breast, lung, and cervical tumors
by exploiting unique electrophoretic mobility and renaturation properties.
Methods: Frozen breast, lung, and cervix cancer tissue lysates and normal organ tissue lysates from the same
human patients were obtained (28 breast tissues, 23 lung tissues, and 23 cervix tissues), minced and homogenized
prior to loading for cathepsin gelatin zymography to determine enzymatic activity.
Results: Cleared bands of cathepsin activity were identified and validated in tumor extracts and detected organ-
and stage-specific differences in activity. Cathepsin K was unique compared to cathepsins L and S. It was
significantly higher for all cancers even at the earliest stage tested (stage I for lung and cervix (n = 6, p < .05), and
stage II for breast; n = 6, p < .0001). Interestingly, cervical and breast tumor cathepsin activity was highest at the
earliest stage we tested, stages I and II, respectively, and then were significantly lower at the latest stages tested
(III and IV, respectively) (n = 6, p < 0.01 and p < 0.05), but lung cathepsin activity increased from one stage to the
next (n = 6, p < .05). Using cathepsin K as a diagnostic biomarker for breast cancer detected with multiplex
zymography, yielded 100% sensitivity and specificity for 20 breast tissue samples tested (10 normal; 10 tumor) in
part due to the consistent absence of cathepsin K in normal breast tissue across all patients.
Conclusions: To summarize, this sensitive assay provides quantitative outputs of cathepsins K, L, and S activities
from mere micrograms of tissue and has potential use as a supplement to histological methods of clinical
diagnoses of biopsied human tissue.
Background
Tumor growth, migration, invasion and metastasis
involves proteolytic activity, and the cathepsin family of
cysteine proteases are proteases that have been impli-
cated in each of these mechanisms, particularly cathe-
psins B, K, L, and S [1,2]. Cathepsin B is one of the more
abundant cathepsins with lysosomal concentrations as
high as one millimolar [3]. Much work has been done on
the collagenolytic abilities of cathepsin B and its role in
tumor metastasis [4,5] by degrading the basement
membrane of tumor cells, but it has an occluding loop
that makes its structure quite different from cathepsins
K, L, and S [6].
Cathepsins K, L, and S are elastinolytic and collageno-
lytic cysteine proteases that share greater than 60%
sequence homology [6], but the variable portions confer
important differences in proteolytic activity and regula-
tory mechanisms. Cathepsin K is the most potent mam-
malian collagenase, capable of cleaving type I collagen in
the native triple helix and in the telopeptide regions
while other collagenases can only cleave at either one site
or the other [7]. It was first thought to be exclusively
expressed in osteoclasts, but there are a number of cell
types that upregulate cathepsin K expression in cancer
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increased in atherosclerosis and cancer as well and is
secreted at sites of inflammation [12-15]. While cathe-
psins K and L prefer acidic environments for optimal
activity, cathepsin S has the unique property of maintain-
ing high elastinolytic activities at neutral pH and has
been shown to be active in angiogenesis, lung cancer, and
emphysema [16-18].
Cathepsin K has been particularly elusive in measuring
its activity in cancer specimens. A number of studies have
implicated cathepsin K expression in cancer progression
and metastasis using cathepsin K inhibitors [19,20],
mRNA analysis [21,22], and immunohistochemical label-
ing of normal and tumor sections [21-23], but the specific
identification and quantification of the mature, active
cathepsin K in these tumors has not been shown. These
studies were important for implicating cathepsin K, but its
transient nature and low levels of expression have made it
difficult to specifically verify the mature form and detect
its activity among a mix of other cathepsin family mem-
bers. Radioactive, fluorescent, or biotinylated active-site
probes have been coupled with blotting and histological
protocols [24], and while they have increased sensitivity to
visualize the mature form in a blot, they still do not pro-
vide measures of proteolytic activity, and cross-reactivity
with other cathepsin family members confuse identifica-
tion. Fluorogenic synthetic amino acid substrates have also
been used to identify a single cathepsin member’s activity
above the others in complex cellular extracts and tissues
[25,26], but due to the high sequence homology, the sub-
strates are promiscuous. Even though one cathepsin may
have a greater affinity and catalytic rate for a substrate, if
another is present at higher concentrations, cross-reactiv-
ity will prevent an accurate measurement [22]. Similar spe-
cificity challenges exist for the use and development of
small molecule inhibitors to cathepsin K [20].
Here, we describe multiplex cathepsin zymography, a
technique that we recently developed that was capable of
detecting cathepsin K activity down to femtomolar levels
of recombinant enzyme and in macrophage derived osteo-
clasts [27]. Cathepsins L and S activity detection is not as
sensitive, most likely due to cathepsin K being a much
more powerful collagenase, but here, we have expanded its
utility and demonstrated its multiplex capacity to detect
cathepsins K, L, and S in cell or tissue preparations from
breast, lung, and cervical tumors to profile cathepsin activ-
ity at increasing stages of cancer progression and provide
a new tool to screen pathological specimens for previously
undetectable cathepsin activity.
Methods
Human Tissues
Breast, lung, and cervix cancer tissue lysates and normal
organ tissue lysates from the same patients were
purchased from Protein Technologies Inc., San Diego,
CA which is facilitated by Integrated Laboratory Ser-
vices-Biotech (ILSbio). The original tumor and normal
tissue specimens were collected from multiple hospitals.
Tissue specimens were collected during the surgery pro-
cess and immediately snap frozen with liquid nitrogen.
ILSbio collected specimens under local Institutional
Review Board approved protocols, ensuring each sample
had patient consent for research purposes. 28 breast tis-
sues, 23 lung tissues, and 23 cervix tissues were obtained
(Table 1). Tumor samples were staged and graded by
pathologists based on the American Joint Committee on
Cancer (AJCC) Staging Manual [28]. Frozen tissues were
minced and homogenized in cold modified RIPA buffer
(PBS, 0.25% sodium deoxycholate, 0.1% SDS, 1 mM
EDTA, 1 mM sodium fluoride, 1 mM sodium orthovana-
date, 1 mM phenylmethanesulfonylfluoride, 1 μg/ml
aprotinin, 1 μg/ml leupeptin, 1 μg/ml pepstatin A), and
clarified by centrifugation. Protein concentrations of the
lysates were normalized to 1 mg/ml.
Gelatin zymography
Cathepsin zymography was performed as described pre-
viously [27]. Briefly, 5X non-reducing loading buffer (0.05%
bromophenol blue, 10% SDS, 1.5 M Tris, 50% glycerol) was
added to all samples prior to loading. Equal amounts of
protein were resolved by 12.5% SDS-polyacrylamide gels
containing 0.2% gelatin at 4°C. Gels were removed and
enzymes renatured in 65 mM Tris buffer, pH 7.4 with 20%
glycerol for 3 washes, 10 minutes each. Gels were then
incubated in activity buffer (0.1 M sodium phosphate buf-
fer, pH 6.0, 1 mM EDTA, and 2 mM DTT freshly added,)
for 30 minutes at room temperature. Then this activity buf-
fer was exchanged for fresh activity buffer and incubated
for 18-24 hours (overnight) incubation at 37°C. The gels
were rinsed twice with deionized water and incubated for
one hour in Coomassie stain (10% acetic acid, 25% isopro-
panol, 4.5% Coomassie Blue) followed by destaining (10%
isopropanol and 10% acetic acid ). Gels were scanned using
an Imagequant 4010 (GE Healthcare). Images were
inverted in Adobe Photoshop and densitometry performed
using Scion Image.
Table 1 Patient Sample Characteristics
Breast Lung Cervix
Normal 10 6 6
Stage I Not Available 6 7
Stage II 6 6 6
Stage III 6 5 4
Stage IV 6 Not Available Not Available
Age (Mean ± SD) 51.2 ± 5.6 56.5 ± 12.8 41.0 ± 11.0
Male/Female 0/28 6/17 0/23
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renatured in 2.5% Triton-X and incubated in 50 mM Tris-
HCl pH 7.4, 10 mM calcium chloride, 50 mM sodium
chloride, 0.05% Triton-X assay buffer overnight. Gels were
imaged using an Imagequant 4010 (GE Healthcare, Wau-
kesha, WI). Images were inverted in Adobe Photoshop
and densitometry was performed using Scion Image.
Representative zymograms shown here have had the levels
adjusted for the entire gel image to improve print viewing
clarity. All human recombinant cathepsins were from
Enzo Life Sciences (Plymouth Meeting, PA). Human
cathepsins K and S were expressed in insect cells, human
cathepsin V was expressed in NSO cells, and human
cathepsin L was isolated from liver.
Western blotting
SDS-PAGE was performed, and protein was transferred
to a nitrocellulose membrane (Bio-Rad) then probed with
monoclonal anti-cathepsin K antibody clone 182-12G5
(Millipore, Billerica, MA) or anti-cathepsin L, or S anti-
bodies (R&D Biosystems, Minneapolis, MN). Secondary
donkey anti-mouse or anti-goat antibodies conjugated to
an infrared fluorophore (Rockland, Gilbertsville, PA)
were used to image protein with a Li-Cor Odyssey scan-
ner (Lincoln, Nebraska).
Statistical Analysis
Results are shown as mean ± SEM of normal and tumor
groups. Student’s unpaired t-test was used to evaluate
statistical significance between two result groups. Values
of p < 0.05 were considered statistically significant. Sen-
sitivity, specificity, and likelihood ratio of the corre-
sponding protease biomarker were calculated across a
range of threshold values with Matlab (Mathworks). To
determine the optimal threshold value that would maxi-
mize sensitivity and specificity, we input the range of
values from zero to the larger value of either the maxi-
mum protease value measured in normal specimens or
the minimum value measured in the cancer specimens.
Threshold window index was calculated according to
the following formula:
(max protease value of max likelihood ratio − minimum protease value of max likelihood ratio)
maximum protease value that maximizes likelihood ratio
Results
Multiplex cathepsin zymography detects mature
cathepsins K, L, and S activity
Mature cathepsins K, L, and S were loaded for cathepsin
zymography and parallel samples were loaded for Wes-
tern blotting to first determine if the zymographically
active bands of cathepsins K, L, and S would appear at
different electrophoretic migration distances. Different
amounts of each cathepsin were loaded to produce clear
bands in the zymogram as they have different limits of
detection by the zymography assay (data not shown).
Cathepsins K, L, and S (1, 50, and 20 ng, respectively) all
appeared as zymographically active bands at distinct
molecular weights (Figure 1); mature cathepsin K band
appeared near the 37 kDa size, cathepsin L at 21 kDa,
and cathepsin S near 25-27 kDa (Figure 1A). Migration
distances (or apparent molecular weights) were com-
pared with the Western blots in figure 1B to verify the
identity of each band. The immunodetected cathepsin K
band is near 37 kDa, cathepsin S exhibited two bands
near 25 kDa, and the cathepsin L protein was detected at
three sizes, but only the smallest of the three immunode-
tected bands was zymographically active (Figure 1B).
Cathepsin zymography detects 50-fold increased
cathepsin K activity in breast cancer specimens
Once it was determined that cathepsins K, L, and S
could be detected with cathepsin zymography, we tested
the hypothesis that cathepsin K activity would be signifi-
cantly increased in breast cancer tissue compared to
normal tissue, and that zymography would detect these
differences. Equal amounts of breast tissue protein (10
μg) were loaded for cathepsin zymography and quanti-
fied by densitometry (Figure 2A). In these ten patient-
matched breast cancer tissue specimens tested, cathe-
psin K activity was 50-fold higher than the activity in
normal breast tissue (n = 10, p < .002), cathepsin L was
9-fold higher (n = 10, p < .005), and cathepsin S was 3-
fold higher but not statistically significant (Figure 2B).
Patient and tumor information is given in Table 1.
Matrix metalloproteinases (MMPs) are another family of
proteases that are metal dependent endopeptidases impli-
cated in cancer development and metastasis [29,30].
MMP-2 and -9 are among the most studied members and
gelatin zymography identifies their activity, but the assay
buffer for optimal activity is different pH and composition
than that for cathepsins as described here. Incubation of
cathepsin zymography gels in acidic conditions drastically
reduces the activity of MMPs and serine proteases, and
the addition of EDTA, a calcium and zinc chelator, to the
assay buffer also prevents activation of the calcium depen-
dent calpains and MMPs to promote cathepsin selectivity.
To determine if MMP activity was as upregulated in
tumor specimens as the cathepsin activity, the same tissue
specimens from Figure 2A were loaded for MMP zymo-
graphy. Tumor MMP-2 and -9 activities were only 2-3
fold greater than normal tissue (Figure 2 C, D p < .05);
much less than the 50- and 9-fold increases found in the
cathepsin K and L zymograms, respectively.
Stage-specific differences in cathepsins K, L, and S in
human breast cancer
We next wanted to determine any stage specific differ-
ences in breast cancer cathepsin activity using this
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Page 3 of 12Figure 1 Multiplex cathepsin zymography detects mature cathepsin K, L, and S activity at distinct migration distances. A) Human
recombinant cathepsins K (1 ng), L (50 ng), and S (20 ng) were loaded for cathepsin gelatin zymography (left) and B) Western blotting. Arrow is
used to indicate the zymographically active band on cathepsin L blot.
Figure 2 Cathepsins K, L, and S activity detection in human breast tissue. A) 10 μg of normal and tumor breast tissue from patient
biopsies were loaded for zymography. Cathepsin K band is visible at 37 kD, cathepsin L at 21 kD, and cathepsin S at 25 kD. Representative
zymogram is shown and cropped for clarity. B) Cathepsin activities were quantified with densitometry of each band on the gel. C) The same
samples were loaded for MMP zymography. A representative MMP zymogram is shown and cropped for clarity. D) Pro- and mature MMP-9 and
MMP-2 activities were quantified by band densitometry. All values are fold change of tumor compared to normal (n = 10, #p < .005, *p < .002,
** p < .05).
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mens each of stages II, III, and IV breast tumor tissue
(as determined by the TNM staging system according to
AJCC Staging Manual) and normal tissues were
obtained and loaded for cathepsin zymography. Stage I
and premalignant breast tissue samples were unavailable
to us. Cathepsin activity peaked at stage II and declined
through stages III and IV (Figure 3A, B). It is important
to note that for cathepsin K, tumor activity at all stages
tested in these samples was significantly higher than the
normal breast tissue activity by 10- to 30-fold (n = 5-8,
*p < 0.05, **p < 0.01, #p < 0.0001) (Figure 3B). Cathe-
psin L activity was significantly higher than normal at
stages II and III (n = 6, p < .05), but not at stage IV,
and due to variability among the five samples tested at
each stage, there was no significant increase in cathepsin
S activity (n = 6).
Utility of cathepsin K zymography as a clinical biomarker
assay for breast cancer detection
Patient-to-patient variation in cathepsin K and L activity
was assessed to determine if a threshold value of
cathepsin K activity could be set that, once crossed
would indicate a positive cancer specimen, (Figure 4A).
Absolute amounts of cathepsin K activity per 10 μg
breast tissue protein was determined by loading increas-
ing doses of recombinant cathepsins K and L in the
same gel as the breast cancer and normal specimens to
generate a standard curve to which the specimen signal
could be fit. Across all ten normal specimens, cathepsin
K measurements were between 0 and 0.03 ng per 10 μg
of tissue protein (Figure 4B). For the cancer samples,
the range of values of cathepsin K were from 0.112 ng
to 0.8 ng per 10 μg of tissue protein (Figure 4B), up to
almost two orders of magnitude higher than any of the
normal specimens. The patient variability for cathepsin
L is shown as well but was not as consistently low for
the normal specimens or as consistently high for the
tumor specimens (Figure 4B).
Sensitivity and specificity analyses were performed to
quantify the probability of a sample being correctly or
incorrectly diagnosed by zymography for cathepsins K
and L. Likelihood ratios were calculated to select the
maximum sensitivity and specificity for each protease
Figure 3 Stage-specific differences in cathepsins K, L, and S in human breast cancer. A) 10 μg of total protein from breast tissues from
stage II-IV from normal and cancer breast tissues were loaded for multiplex cathepsin zymography, and a representative zymogram is shown
and cropped for clarity. B) Cathepsins K, L, and S activities were quantified by band densitometry (n = 5, *p < 0.05, **p < 0.01, #p < 0.0001).
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hood ratio is maximized are highlighted by the yellow
b o x( F i g u r e4 C ) .C a t h e p s i nKw a st h eo n l ye n z y m eo f
those tested that reached 100% sensitivity and 100% spe-
cificity across the twenty breast tissue specimens of this
study. Cathepsin L sensitivity and specificity values were
80% and 100%, respectively (Figure 4). MMP-2 sensitiv-
ity and specificity were 60% and 90%, and MMP-9 had
values of 80% and 90% (Table 2, Additional File 1). A
threshold window index was calculated for each pro-
tease as the ratio of the difference in the range of values
that maximize likelihood ratio to the maximum poten-
tial threshold value. The results are shown in Table 2
with cathepsin K having the largest threshold window
index (72%) to provide this maximum sensitivity and
specificity.
Cathepsins K, L, and S activity profiles in human lung
cancer
With successful detection of mature cathepsins K, L,
and S in human breast cancer tissue, other types of
Figure 4 Cathepsin K zymography potential as a clinical diagnostic tool for breast cancer . A) Normal and tumor breast tissue
zymograms were compared for patient-to-patient variation. Standard dose curves of recombinant cathepsin K (0.2, 0.5, 1, and 5 ng) and
cathepsin L (45, 220, 450, and 900 ng) were loaded per gel for quantifying absolute quantities of cathepsins K and L. B) Cathepsins K and L
activity were quantified with densitometry and compared to the standard curve generated to semi-quantitatively determine nanograms of active
enzyme. C) Sensitivity (blue line), specificity (red line), and likelihood ratio (dotted black line) were calculated over a range of values to identify
an optimal threshold value for cathepsins K and L that would distinguish normal samples from tumor samples. Yellow boxes outline the region
of maximal likelihood ratio.
Table 2 Range of threshold values at maximal likelihood
ratio and associated sensitivity and specificity values for
each protease tested
Range Enzyme Index Sensitivity Specificity
.03-0.11 ng Cathepsin K 72% 100% 100%
40-55 ng Cathepsin L 27% 100% 80%
4639-5009 AU MMP-9 7% 80% 90%
6447-7063 AU proMMP-9 9% 70% 90%
5334-5872 AU MMP-2 9% 60% 90%
4762-5541 AU proMMP-2 14% 80% 80%
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Page 6 of 12tumors were investigated to establish broader utility of
this assay as a screen for multiple cathepsins in one tis-
sue specimen. Cathepsin K had been previously identi-
fied immunohistochemically in lung tumor specimens
[31,32], but the active mature enzyme had not been
measured. Normal and tumor lung tissue specimens
from stages I, II, and III were obtained, and loaded for
cathepsin zymography (Figure 5A). Lung tumor speci-
mens had a statistically significant increase over normal
tissue in cathepsin K (2-3 fold) and cathepsin S (5-6
fold), but not for cathepsin L (~2-3 fold, p = .07) across
all stages tested (Figure 5B). Comparisons were then
made between stages to measure lung tumor stage-spe-
cific differences in cathepsin activity. Cathepsins K, L,
and S activity all increased with lung tumor stage, but
most notably, only cathepsin K showed a statistically
significant increase in activity as early as stage I (Figure
5C). Cathepsins L and S were significantly higher than
normal by stages II and III for the lung tumor speci-
mens tested (Figure 5C).
Increased cathepsin K in human cervical cancer
specimens
Multiple proteases have been shown to be related to cer-
vical cancer development [33,34], but there have been no
reports of cathepsin K involvement. Normal and tumor
cervical tissue specimens from stages I, II, and III were
obtained and loaded for multiplex cathepsin zymography
(Figure 6A). Human recombinant cathepsins K, L, and S
positive controls were loaded as well to confirm cervical
cathepsin identity. The dominant cathepsin active in the
zymography of cervical tumor extracts was cathepsin K
(Figure 6A); cathepsin K activity was highest at stages I
and II, but not significantly different in stage III cervical
tumors (Figure 6B).
Cervical tumor specimens’ cathepsin K activity dis-
played a wide range of patient-to-patient variability, as
seen in the box-whisker plot, and, as a result, compari-
sons of all normal samples to all tumor samples was not
statistically significant. However, there were significant
differences determined between normal cervical tissue
Figure 5 Cathepsins K, L, and S activity profiles in human lung cancer. A) Different stages (I, II, and III) of lung cancer and normal lung
tissues were obtained and prepared as described. 10 μg of protein were loaded for multiplex cathepsin zymography, and a representative
zymogram is shown and cropped for clarity. B) Cathepsin K, L, and S activities were quantified by densitometry. Cathepsin activity from 24
samples (18 cancer and 6 normal) comparing normal to tumor is shown. C) Comparisons of cathepsins K, L, and S activity changes at different
stages of tumor progression (n = 4-6, *p < 0.05).
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that of stage III (Figure 6B). To remove patient-to-patient
variability as a confounding factor, we analyzed the com-
bined data using only paired normal and malignant cervi-
cal tissue from the same patient (n = 5). In figure 6C,
cathepsin K activity in the cervical tumor is significantly
increased by 10-fold for an individual above her own
basal normal tissue activity levels (n = 5, p < .05).
Comparison of cathepsin activity among different organs
To compare cathepsins K, L, and S activity across all
three tissues tested and observe any differences in nor-
mal baseline signatures as well as cancer-mediated
increases, 10 μg of protein from each organ, normal and
tumor, were loaded into one zymogram (Figure 7A).
Lung baseline and tumor activity was higher than both
breast and cervix. In order to quantify differences in
organ specific increases in cathepsin activity from nor-
mal to tumor, cathepsin activity was normalized to the
maximum signal for each organ and presented as box-
whisker plots (Figure 7B). For breast, lung, and cervix
tissue, the tumor specimens showed increased cathepsin
K activity, with minimal to no detection in normal tissue
(Figure 7B). Cathepsin K activity was elevated in the
tumor samples of all three cancers tested: breast, lung,
and cervix (Figure 7B).
Discussion
Multiplex zymography’s utility as a supplemental screen-
ing tool of pathological specimens was effectively shown
here to profile cathepsin K, L, and S activities in breast,
lung, and cervical tissue at three different stages of tumor
Figure 6 Increased cathepsin K in human cervical cancer specimens. A) Tumor tissues from stages I-III cervical cancer and normal tissues
were obtained and prepared as described. 10 μg of protein were loaded for multiplex cathepsin zymography, and a representative zymogram
with protein ladder (lad), cathepsin K, L and S positive controls is shown and cropped for clarity. B) Cathepsins K, L, and S activities were
quantified by band densitometry and represented by the box and whisker plot shown to exhibit patient to patient variability. For box and
whisker plots, the top and bottom of the box represent the 75
th and 25
th quartile, and whiskers +1.5 SD and -1.5 SD, respectively (n = 4-7, #p <
0.05 compared to normal). C) Patient-matched comparisons of normal to tumor cervical tissue cathepsin K activity yielded an increase of ~12
fold (n = 5, *p < 0.05).
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this one assay after clinical grading of the biopsied tissue
indicating that quantitative comparisons with cathepsin
zymography can supplement the gold standard histologi-
cal methods of determining whether biopsied tissue is
cancerous or not.
Differences in organ and tissue structure or predomi-
nant extracellular matrix (ECM) components may be
responsible for the differences in cathepsin K, L, and S
activity profiles between breast, lung, and cervical tissue
and changes to these profiles as the cancer stage
increased. Ductal carcinoma breast cancers arise in the
inner layer of mammary duct in the columnar epithe-
lium that lines it, and are surrounded by lobes, stromata,
and adipose tissues. Squamous cell carcinoma of the
cervix starts in the epithelium of cervix and invades into
Figure 7 Comparisons of different organ samples. A) Normal and tissue samples from the three organs (breast, lung and cervix) were
obtained and prepared as described. 10 μg of protein were loaded for multiplex cathepsin zymography, and a representative zymogram is
shown and cropped for clarity. B) Cathepsin K data was normalized by maximum cathepsin K activity value for each organ and represented by
the box and whisker plot. For box and whisker plots, the top and bottom of the box represent the 75
th and 25
th quartile, and whiskers +1.5 SD
and -1.5 SD, respectively.
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Page 9 of 12the underlying stroma. Lung tumors, however, that
mainly arise in the bronchi, are surrounded by hyaline
cartilage, a tough connective tissue made of high density
of collagen II and is also in a much more dynamic
environment as the diaphragm contracts and relaxes
during breathing. ECM proteins [15], mechanical forces
[14,35], native and infiltrating cell types [36,37], and cell
transformation [2,38] have all been linked to upregula-
tion of different cathepsin family members and all may
contribute to the organ-specific differences seen here.
Cathepsin secreting alveolar macrophages are regularly
present in the lungs [39] and may contribute to the
higher baseline of cathepsin activities in lung tissues
compared to breast and cervical tissues (Figure 7).
Of the three types of cancer and the three cathepsins
studied, cathepsin K in breast tissue was especially
unique in that its activity was binary: off in normal tis-
sue and on in cancerous tissue. Cathepsin K in breast
tissue had the lowest variability and consistently low
baseline for cathepsin K activity in the normal tissue,
compared to breast, lung, and cervical cancer tissue
(Figure 4). This suggests that across a number of
patients, the background and basal activity is low for
healthy, noncancerous breast tissue tempting considera-
tion of using cathepsin zymography for clinical detection
of breast cancer. A potential clinical workflow closely
resembles that of the one followed for these specimens
prior to reaching our lab for examination: 1) lump
detection by self exam or mammogram, 2) visit to doc-
tor, 3) biopsy of small piece of tissue, 4) histological
assessment performed by pathologist, and 5) zymogra-
phy from 10 μg biopsied tissue protein and comparison
to threshold value. A greater number of clinical speci-
mens will need to be assessed to determine efficacy of
zymography in practice, prior to clinical grading, but the
results shown here with 100% sensitivity and 100% spe-
cificity are promising.
Higher patient-to-patient variability of cathepsin levels
within lung and cervical cancer specimens tested here
may be due to the source of the tumorigenicity for each
organ. National Cancer Institute reports that smoking is
the leading cause of lung cancer deaths: 90 percent for
men and 80 percent for women (NCI 2010), and differ-
ences in smoking habits and tobacco delivery methods
m a yb et h ec a u s eo ft h ev a r i a b i l i t yd e t e c t e db yt h i s
assay. Despite the variability within a stage of lung can-
cer, there was still a statistically significant increase in
cathepsin activity compared to normal. Again, cathepsin
K activity stood out as being significantly upregulated
even at stage I of lung cancer, where cathepsin L and S
did not reach this point until stage II (Figure 5C).
Unique upregulation of cathepsin K in lung tumors also
seems to be a candidate biomarker for early confirma-
tion of lung cancer detection.
Human papilloma virus (HPV) infection is a leading
cause of cervical cancer [33] and has been shown to
influence cathepsin levels in mouse models of cervical
cancer [40]. Different strains of HPV have different
amplification and oncogenicity [33], and may be
reflected in the variations of the human cervical cancer
results (Figure 6B). We were not aware of HPV status of
any of the specimens. However, there was still a signifi-
cant increase in cathepsin K activity in cancerous cervi-
cal tissue when compared to normal cervical tissue from
that same patient (Figure 6C). This patient-matched
data for six women corroborates evidence that cervical
tumors express greater levels of cathepsin K activity
once the patient variability factor was removed.
Pap smears are routinely performed to screen for cer-
vical cancer. Small samples of cervical tissue are biop-
sied and clinical and pathological grading of the
histology is performed to observe any abnormal cells in
the samples. Given the results shown here with a 10-
fold increase in cathepsin K activity detected from 10 μg
of tissue protein, cathepsin zymography may serve as a
supplemental biomarker to aid the assessment of incon-
clusive Pap smear results. Again, more clinical samples
will need to be tested to verify its utility, but cathepsin
K also presented an on/off activity in cancer vs. normal
cervical tissue, similarly to breast tissue.
Cervical and breast cancer cathepsin activity peaked at
the earliest stage we tested, stages I and II, respectively,
and then were significantly less at the latest stage tested.
This non-intuitive change in cathepsin activity in the
primary tumor has not previously been shown. Tumor
cell heterogeneity may provide one possible explanation.
Our hypothesis is that the more metastatically inclined
cells in the primary tumor are producing more cathe-
psin proteases to facilitate departure from the primary
tumor site; when they leave the primary tumor, the
source of the proteolytic activity leaves as well. This
finding may guide improved stage specific treatments
for tumors and indicate more rigorous protease inhibi-
tion strategies at primary tumors to block the earliest
steps of metastasis.
It is important to note this zymography assay samples
the entire tumor, not just the tumor cells. Therefore,
any tumor associated macrophages, blood vessels, white
blood cells, or any other infiltrating cells with cathepsin
activity will be captured in that tissue extract. Aggressive
tumor cells are able to recruit the surrounding stromal
cells to enhance tumor growth. Tumor associated
macrophages expressing cathepsins were shown to orga-
nize around the tumor edge at later stages in a pancrea-
tic cancer animal model [36], indicating that there is
cellular recruitment and organization that may promote
metastasis. Their combined activities contribute to
tumor metastatic potential and this zymography assay
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raises the issue of whether cathepsin K zymography will
be able to differentiate cancer from benign tissue hyper-
trophies and inflammatory diseases. As macrophages
actively participate in most of immune responses, ele-
vated cathepsin activities at inflammatory situations
are theoretically possible and need to be further tested
with clinical samples. Fluorescent activity based probes
(ABP) in tissue sections provide incredible resolution of
cathepsin activity [41] and, used in conjunction with
zymography, can provide a two-prong identification
approach: ABP on tissue slices with cell-specific immu-
nohistochemical labelling can identify cell types produ-
cing cathepsins, and zymography can identify the type
and quantity of cathepsin being produced.
Conclusions
Overall, the application of multiplex cathepsin zymogra-
phy to breast, lung, and cervical cancer specimens have
highlighted the unique upregulation of cathepsin K in
all three of these cancers tested and even in the earliest
stages measured. Altogether, this elevates cathepsin K
potential to be a cancer biomarker for breast, lung, and
cervical cancer, but more broadly, highlights its potential
to be a biomarker for other types of cancer that have
not previously been investigated. Histological studies
benefit from quantitative, visual confirmation offered by
cathepsin zymography using just a small piece of the
biopsied tissue. As an added benefit to researchers, this
assay does not require antibodies, which expands its
application to other species, including the numerous
mouse models of cancer that have been developed. Lack
of antibodies also significantly reduces cost compared to
immunobased methods such as ELISA, Western blot-
ting, and immunohistochemistry, as well as minimizing
concerns of nonspecific antibody binding and pro-cathe-
psin detection interference. Employing such multiplex
technologies, that can screen samples inexpensively, will
provide a broader net to catch new biomarkers and etio-
logical agents to direct investigation into previously
untested mechanisms and inhibitory targets.
Additional material
Additional files 1: Diagnostic performance of MMP-2 and MMP-9 for
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ratio (dotted black line) were calculated and plotted over a range of
values to identify an optimal threshold value for MMP-2 and MMP-9 that
would distinguish normal samples from tumor samples. Yellow boxes
outline the region of maximal likelihood ratio.
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